Untersuchung von Translationalem Readthrough bei Peroxisomalen Biogenesestörungen im Zellmodell

von Mirco Schilff
Dissertation
Datum der mündl. Prüfung:2025-06-18
Erschienen:2025-05-19
Betreuer:Prof. Dr. Sven Thoms
Gutachter:Prof. Dr. Sven Thoms
Gutachter:Prof. Dr. Ralph Kehlenbach
Förderer:Promotionskolleg für Medizinstudierende der Universitätsmedizin Göttingen, Else Kröner-Fresenius-Kolleg, Jacob-Henle-Programm
Förderer:Promotionskolleg für Medizinstudierende der Universitätsmedizin Göttingen, Else Kröner-Fresenius-Kolleg, Jacob-Henle-Programm
Zum Verlinken/Zitieren: http://dx.doi.org/10.53846/goediss-11267

 

 

Dateien

Name:Dissertation_Schilff_Mirco_eDiss.pdf
Size:3.55Mb
Format:PDF
Description:Dissertation Schilff, MIrco

Lizenzbestimmungen:

Zusammenfassung

Englisch

Premature termination codon (PTC) mutations account for approximately 10% of pathogenic variants in monogenic diseases. Stimulation of translational readthrough, also known as stop codon suppression, using translational readthrough-inducing drugs (TRIDs) may serve as a possible therapeutic strategy for the treatment of genetic PTC diseases. One important parameter governing readthrough is the stop codon context (SCC)—the stop codon itself and the nucleotides in the vicinity of the stop codon on the mRNA. However, the quantitative influence of the SCC on treatment outcome and on appropriate drug concentrations are largely unknown. Here, we analyze the readthrough-stimulatory effect of various readthrough-inducing drugs on the SCCs of five common premature termination codon mutations of PEX5 in a sensitive dual reporter system. Mutations in PEX5, encoding the peroxisomal targeting signal 1 receptor, can cause peroxisomal biogenesis disorders of the Zellweger spectrum. We show that the stop context has a strong influence on the levels of readthrough stimulation and impacts the choice of the most effective drug and its concentration. These results highlight potential advantages and the personalized medicine nature of an SCC-based strategy in the therapy of rare diseases.
Keywords: translational readthrough; rare disease; peroxisome; peroxisome biogenesis disorder; PEX5; personalized medicine; readthrough therapy; aminoglycoside; translational readthrough; rare disease; peroxisome; peroxisome biogenesis disorder; PEX5; personalized medicine; readthrough therapy; aminoglycoside
 
Statistik